This lecture reviews the clinical use of sphingosine-1-phosphate (S1P) receptor modulators in Multiple Sclerosis, with a focus on their mechanisms of action, receptor selectivity, pharmacokinetics, and safety considerations. Magd Zakaria discusses how differences in half-life, metabolism, and receptor targeting influence efficacy, adverse events, monitoring requirements, and treatment sequencing, including switching strategies and special populations such as women planning pregnancy.
Key Insights from the Lecture:
- S1P receptor modulators exert their therapeutic effect by modulating lymphocyte trafficking and acting on central nervous system cells, but also share off-target effects driven mainly by S1P1 receptor stimulation.
- Differences between agents are largely explained by receptor selectivity, half-life, and metabolic pathways, which directly impact elimination time, safety, and rebound risk.
- Fingolimod has demonstrated efficacy in highly active relapsing Multiple Sclerosis and pediatric populations, but is associated with a higher risk of prolonged lymphopenia, cardiac effects, infections, and rebound after discontinuation.
- Cardiac effects, macular edema, infections (including herpes zoster), malignancies, liver enzyme elevation, and respiratory changes are class-related adverse events requiring systematic monitoring.
- Switching from S1P modulators requires careful timing to avoid disease rebound, with monoclonal antibodies appearing more effective than immune reconstitution therapies in preventing reactivation.
- Siponimod is supported by randomized controlled evidence in active secondary progressive Multiple Sclerosis, showing benefits including effects on cognition, and requires CYP2C9 genotyping to guide dosing.
- All S1P modulators are contraindicated in pregnancy, with longer washout periods and higher rebound risk associated with agents with longer half-lives.
“Sphingosine system – Clinical aspects: available and future treatment“.
Please subscribe to watch.
About the speaker:
Magd Zakaria
Head of the Multiple Sclerosis Unit at the Ain Shams Specialized University Hospital
Magd Zakaria obtained his medical degree from the Medical School of Ain Shams University in 1980 where he graduated with honors. He completed his residency and obtained his Master’s Degree in Neuropsychiatry at the Neuropsychiatric Department of Ain Shams University in 1984. Prof. Zakaria became Assistant Lecturer in 1989 and thereafter obtaining his MD degree in Neurology in 1989. Prof. Zakaria became Assistant Professor of Neurology in 1994 and Professor of Neurology since 1999 until now. He was Head of the Neurology Department at the Ain Shams Specialized University Hospital in 1990 and Head of the Stroke Unit in 1991. Since 2014, Prof. Zakaria has become the Head of the Multiple Sclerosis Unit at the Ain Shams Specialized University Hospital.
Prof. Zakaria is currently the President of the Egyptian Society of Multiple Sclerosis and a member of the editorial board of the journal MSARD (Multiple Sclerosis and Related Disorders). He is also a member of the MENACTRIMS assembly board and Egypt’s Brain Health Champion (MS Brain Health Organization).
Prof. Zakaria was also the head of the Neuropsychiatric Department of the Ain Shams medical school from August 2015 till July 2017.
Media
Details
We value your opinion.
